RXST Class Action Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the RxSight, Inc. Class Action
1. Class action filed against RxSight for misleading demand disclosures. 2. Significant declines in LDD sales and LAL utilization reported on July 8, 2025. 3. Full year 2025 guidance lowered by about $42.5 million midpoint. 4. Stock price plummeted 37.8% to $7.95 following negative financial results. 5. Shareholders may participate as lead plaintiffs in the class action.